Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Operating Income (2016 - 2025)

Spyre Therapeutics' Operating Income history spans 11 years, with the latest figure at -$57.2 million for Q4 2025.

  • For Q4 2025, Operating Income rose 6.66% year-over-year to -$57.2 million; the TTM value through Dec 2025 reached -$209.6 million, changed 0.48%, while the annual FY2025 figure was -$209.6 million, 0.48% changed from the prior year.
  • Operating Income reached -$57.2 million in Q4 2025 per SYRE's latest filing, roughly flat from -$56.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$6.7 million in Q2 2021 to a low of -$159.2 million in Q2 2023.
  • Average Operating Income over 5 years is -$40.5 million, with a median of -$33.2 million recorded in 2022.
  • Peak YoY movement for Operating Income: crashed 610.19% in 2023, then soared 72.28% in 2024.
  • A 5-year view of Operating Income shows it stood at -$20.4 million in 2021, then rose by 6.26% to -$19.2 million in 2022, then plummeted by 139.61% to -$45.9 million in 2023, then plummeted by 33.41% to -$61.3 million in 2024, then increased by 6.66% to -$57.2 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Operating Income are -$57.2 million (Q4 2025), -$56.9 million (Q3 2025), and -$41.9 million (Q2 2025).